For US Healthcare Professionals US Prescribing Information Medication Guide CHOOSE INDICATIONDrugDrug name X NVAF: Reducing stroke risk Chronic CAD/PAD: Reducing the risk of major CV events DVT/PE: Initial Treatment DVT/PE: Extended Treatment DVT Prophylaxis: After hip/knee replacement surgery VTE Prophylaxis: Acutely ill medical patients Home Dual Pathway Inhibition ESC Guidelines Clinical Trial COMPASS patient population COMPASS study design Efficacy Profile Chronic CAD/PAD additional outcomes Chronic CAD/PAD major CV events Safety Profile Chronic CAD/PAD safety profile Chronic PAD subgroup safety profile Dosing Home Extensive Evidence Efficacy Profile ITT population Safety, as-treated population ROCKET AF obesity subgroup NVAF and morbid obesity real-world study Safety Profile ROCKET AF safety profile ROCKET AF obesity subgroup NVAF and obesity real-world study Dosing Dose information Renal information Home Extensive Evidence Efficacy Profile EINSTEIN PE EINSTEIN DVT HoT-PE MERCURY PE Safety Profile EINSTEIN PE EINSTEIN DVT HoT-PE Dosing Dose information Starter Pack Home Clinical Trial Efficacy Profile EINSTEIN CHOICE INDEX PE OBESITY Safety Profile EINSTEIN CHOICE INDEX PE Dosing Dose information Renal Information Home Extensive Evidence Efficacy Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Safety Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Dosing Home Clinical Trial Efficacy Profile Safety Profile Dosing DOSING SWITCH AND MANAGEMENT Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration options ACCESS AND SUPPORT Request XARELTO® Samples Formulary Finder Janssen CarePath Program Janssen Prescription Assistance RESOURCES Reprints Patient resources Professional resources Other resources FAQs SEARCH XARELTO® DOSING: ALL INDICATIONS Search Important Safety Information US Prescribing Information Medication Guide For Non-US Visitors Patient Site Change Indication Choose Indication NVAF: Reducing stroke risk Extensive evidence Efficacy profile Safety profile Dosing Chronic CAD/PAD: Reducing the risk of major CV events Clinical Trials Efficacy profile Safety profile Dosing DVT/PE: Initial treatment Extensive evidence Efficacy profile Safety profile Dosing VTE Prophylaxis: Acutely ill medical Clinical trial Efficacy profile Safety profile Dosing DVT/PE: Extended treatment Clinical trial Efficacy profile Safety profile Dosing DVT Prophylaxis: After hip/knee replacement surgery Extensive evidence Efficacy profile Safety profile Dosing Home Dual Pathway Inhibition ESC Guidelines Clinical Trial COMPASS patient population COMPASS study design Efficacy Profile Chronic CAD/PAD additional outcomes Chronic CAD/PAD major CV events Safety Profile Chronic CAD/PAD safety profile Chronic PAD subgroup safety profile Dosing Home Extensive Evidence Efficacy Profile ITT population Safety, as-treated population ROCKET AF obesity subgroup NVAF and morbid obesity real-world study Safety Profile ROCKET AF safety profile ROCKET AF obesity subgroup NVAF and obesity real-world study Dosing Dose information Renal information Home Extensive Evidence Efficacy Profile EINSTEIN PE EINSTEIN DVT HoT-PE MERCURY PE Safety Profile EINSTEIN PE EINSTEIN DVT HoT-PE Dosing Dose information Starter Pack Home Clinical Trial Efficacy Profile EINSTEIN CHOICE INDEX PE OBESITY Safety Profile EINSTEIN CHOICE INDEX PE Dosing Dose information Renal Information Home Extensive Evidence Efficacy Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Safety Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Dosing Home Clinical Trial Efficacy Profile Safety Profile Dosing DOSING SWITCH AND MANAGEMENT Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration options ACCESS AND SUPPORT Request XARELTO® Samples Formulary Finder Janssen CarePath Program Janssen Prescription Assistance RESOURCES Reprints Patient resources Professional resources Other resources FAQs SEARCH XARELTO® DOSING: ALL INDICATIONS
NVAF: Reducing stroke risk Extensive evidence Efficacy profile Safety profile Dosing Chronic CAD/PAD: Reducing the risk of major CV events Clinical Trials Efficacy profile Safety profile Dosing DVT/PE: Initial treatment Extensive evidence Efficacy profile Safety profile Dosing VTE Prophylaxis: Acutely ill medical Clinical trial Efficacy profile Safety profile Dosing DVT/PE: Extended treatment Clinical trial Efficacy profile Safety profile Dosing DVT Prophylaxis: After hip/knee replacement surgery Extensive evidence Efficacy profile Safety profile Dosing
XARELTO®: COMPASS clinical trial in chronic CAD/PAD XARELTO®: COMPASS clinical trial in chronic CAD/PAD